Pricing Log in Create free account

Enliven Therapeutics, Inc. (ELVN) vs Parabilis Medicines, Inc. (PBLS)

Enliven Therapeutics, Inc. and Parabilis Medicines, Inc. are both Biotechnology companies. Enliven Therapeutics, Inc. and Parabilis Medicines, Inc. are of similar size ($3.4B and $3.3B). Across the 9 metrics below, Enliven Therapeutics, Inc. leads on 5 and Parabilis Medicines, Inc. on 4.

Valuation

Metric ELVN PBLS Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 3.64 0.79 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 1.67 0.66
EV/Sales n/m n/m 9.02
Earnings yield (3.39%) (290.38%) (32.88%)
Free cash flow yield (2.05%) (14.42%) (23.13%)

Profitability

Metric ELVN PBLS Biotechnology median
Gross margin 0.00% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (15.31%) 0.00% (51.96%)
Return on assets (14.98%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ELVN PBLS Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 3.17% (10.69%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ELVN PBLS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 64.07 17.91 4.97
Net debt to EBITDA 3.87 0.09 1.01

Dividend

Metric ELVN PBLS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ELVN PBLS Biotechnology median
Market cap 3.28b 3.44b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack